ENTA
Enanta Pharmaceuticals, Inc.
Set alert
10.71 USD -0.44 -3.95%
10.71 Day range 11.09
10.71 52-week range 16.85
- YTD
- -32.09%
- 1 year
- -1.38%
- Open
- 11.05
- Prev close
- 11.15
- Mkt cap
- 311.93M
- Vol
- 202.34K
- Avg vol
- 247.71K
- EPS
- -2.42
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.71
- High
- 11.09
- Forward P/E
- -1.32
- Beta
- 0.57
- Short ratio
- 20.91
- Inst. own
- 100.66%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 5, 2025
- 50-d avg
- 9.78
- 200-d avg
- 12.44
- 1y target
- 16.88
Key statistics
- Market cap
- 135.01M
- Enterprise value
- 187.00M
- Trailing P/E
- 0.00
- Forward P/E
- -1.32
- PEG ratio
- 0.00
- Price / sales
- 1.88
- Price / book
- 0.91
- EPS (TTM)
- -5.48
- Beta
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -160.27%
- Revenue (TTM)
- 71.96M
- Revenue growth
- -4.90%
- Free cash flow
- -63.27M
- Total cash
- 230.08M
- Total debt
- 226.17M
- Return on equity
- -59.64%
- Shares outstanding
- 21.19M
- Short % of float
- 17.26%
- 50-day average
- 9.78
- 200-day average
- 12.44
Analyst view
Consensus: buy
Buy
Price target (mean) 16.88 +57.6% upside
Now 10.71
- Target (low)
- 9.00
- Target (mean)
- 16.88
- Target (high)
- 27.00
Ratings (0m) 8 4 buy · 3 hold · 1 sell
- Strong buy2
- Buy2
- Hold3
- Sell0
- Strong sell1
Next earnings
Feb 5, 2025
Expected Feb 5, 2025. Consensus EPS estimate -1.27.
Financials — quick view
ENTA Revenue — quarterly 14.36M
ENTA Net income — quarterly -19.50M
ENTA EPS — quarterly -0.67
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 5, 2025 | Dec 1, 2024 | -1.15 | — | — | — |
| Nov 25, 2024 | Sep 1, 2024 | -1.16 | -1.36 | -0.20 | -17.24% |
| Aug 5, 2024 | Jun 1, 2024 | -1.49 | -1.07 | +0.42 | +28.19% |
| May 6, 2024 | Mar 1, 2024 | -1.26 | -1.47 | -0.21 | -16.67% |
| Feb 7, 2024 | Dec 1, 2023 | -1.18 | -1.58 | -0.40 | -33.90% |
| Nov 20, 2023 | Sep 1, 2023 | -2.11 | -1.33 | +0.78 | +36.97% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 26, 2024 | Baird | main | Outperform | Outperform |
| Nov 26, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Oct 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 9, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Sep 27, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Aug 6, 2024 | JP Morgan | main | Underweight | Underweight |
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- enanta.com
News
- Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D.
- Enanta Pharmaceuticals Doses First Patient In Its RESOLVE Phase 2b/3 Clinical Trial Of Zelicapavir In Adults At High Risk Of Severe Outcomes From RSV; Topline Data Expected In 2027
- Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
- Enanta Pharmaceuticals To Present Data For Zelicapavir, Oral, Once-Daily, N-Protein Inhibitor In Development For Treatment Of Respiratory Syncytial Virus At IDWeek 2026
- Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
- Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH)
- HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target
- Bank of America Corp DE Reduces Stake in Enanta Pharmaceuticals, Inc. $ENTA
- Enanta Pharmaceuticals to Participate in September Investor Conferences
- Enanta Pharmaceuticals to Participate in September Investor Conferences
Your note
Sign in to keep a note on ENTA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GARDINER NATHANIEL S | Officer | Conversion of Exercise of derivative security | Feb 25, 2024 | 111,614 |
| KIEFFER TARA LYNN | Officer | Sale | Dec 5, 2024 | 29,305 |
| LULY JAY R | Chief Executive Officer | Sale | Dec 5, 2024 | 801,638 |
| LUU BRENDAN | Officer | Sale | Dec 5, 2024 | 36,047 |
| MELLETT PAUL J JR | Chief Financial Officer | Sale | Dec 5, 2024 | 91,710 |
| OR YAT SUN | Officer | Sale | Dec 5, 2024 | 369,109 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Farallon Capital Management LLC | 9.95% | 2,108,262 | 13.43M | Sep 29, 2024 |
| Vanguard Group Inc | 9.35% | 1,981,866 | 12.62M | Sep 29, 2024 |
| Blackrock Inc. | 8.97% | 1,900,323 | 12.11M | Sep 29, 2024 |
| Krensavage Asset Management, LLC | 7.07% | 1,498,074 | 9.54M | Sep 29, 2024 |
| Morgan Stanley | 5.20% | 1,102,852 | 7.03M | Sep 29, 2024 |
| Armistice Capital, LLC | 4.72% | 1,000,000 | 6.37M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.97% | 629,597 | 4.01M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.47% | 524,379 | 3.34M | Oct 30, 2024 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 1.42% | 300,762 | 1.92M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.33% | 281,611 | 1.79M | Sep 29, 2024 |
| Vanguard Variable Insurance Fund-Small Company Growth | 1.20% | 253,365 | 1.61M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.96% | 203,264 | 1.29M | Aug 30, 2024 |